BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Belga S, Doucette KE. Hepatitis C in non-hepatic solid organ transplant candidates and recipients: A new horizon. World J Gastroenterol 2016; 22(4): 1650-1663 [PMID: 26819530 DOI: 10.3748/wjg.v22.i4.1650] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 21] [Article Influence: 5.2] [Reference Citation Analysis]
Number Citing Articles
1 Poller W, Kaya Z, Muche M, Kasner M, Skurk C, Kappert K, Tauber R, Escher F, Schultheiss HP, Epple HJ, Landmesser U. High incidence of cardiac dysfunction and response to antiviral treatment in patients with chronic hepatitis C virus infection. Clin Res Cardiol 2017;106:551-6. [PMID: 28236021 DOI: 10.1007/s00392-017-1086-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
2 Yosry A, Gamal Eldeen H, Medhat E, Mehrez M, Zayed N, Elakel W, Abdelmoniem R, Kaddah M, Abdelaziz A, Esmat G, El-Serafy M, Doss W. Efficacy and safety of sofosbuvir-based therapy in hepatitis C virus recurrence post living donor liver transplant: A real life egyptian experience. J Med Virol 2019;91:668-76. [PMID: 30549048 DOI: 10.1002/jmv.25362] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
3 Aslam S, Grossi P, Schlendorf KH, Holm AM, Woolley AE, Blumberg E, Mehra MR; working group members. Utilization of hepatitis C virus-infected organ donors in cardiothoracic transplantation: An ISHLT expert consensus statement. J Heart Lung Transplant 2020;39:418-32. [PMID: 32362393 DOI: 10.1016/j.healun.2020.03.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
4 Ohdan H. Should organs from hepatitis C virus-infected donors be used for transplantation in the era of DAAs? Transpl Int 2017;30:860-2. [PMID: 28419684 DOI: 10.1111/tri.12971] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Stepanova M, Locklear T, Rafiq N, Mishra A, Venkatesan C, Younossi ZM. Long-term outcomes of heart transplant recipients with hepatitis C positivity: the data from the U.S. transplant registry. Clin Transplant 2016;30:1570-7. [DOI: 10.1111/ctr.12859] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
6 Esforzado N, Morales JM. Hepatitis C and kidney transplant: The eradication time of the virus has arrived. Nefrologia (Engl Ed) 2019;39:458-72. [PMID: 30905391 DOI: 10.1016/j.nefro.2019.01.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
7 Theodoropoulos N, Whitson BA, Martin SI, Pouch S, Pope-Harman A. Successful treatment of donor-derived hepatitis C infection in a lung transplant recipient. Transpl Infect Dis 2017;19. [PMID: 28060441 DOI: 10.1111/tid.12659] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
8 Lo DJ, Sayed BA, Turgeon NA. Pancreas transplantation in unconventional recipients. Curr Opin Organ Transplant 2016;21:393-8. [PMID: 27328037 DOI: 10.1097/MOT.0000000000000334] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
9 Khan B, Singer LG, Lilly LB, Chaparro C, Martinu T, Juvet S, Pipkin M, Waddell TK, Keshavjee S, Humar A, Cypel M. Successful Lung Transplantation From Hepatitis C Positive Donor to Seronegative Recipient. Am J Transplant 2017;17:1129-31. [PMID: 27873483 DOI: 10.1111/ajt.14137] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 6.6] [Reference Citation Analysis]
10 Liu CH, Chen YS, Wang SS, Liu CJ, Su TH, Yang HC, Hong CM, Chen PJ, Chen DS, Kao JH. Sofosbuvir-based Interferon-Free Direct Acting Antiviral Regimens for Heart Transplant Recipients With Chronic Hepatitis C Virus Infection. Clin Infect Dis 2018;66:289-92. [PMID: 29020359 DOI: 10.1093/cid/cix787] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
11 Lee SJ, Kim KH, Hong SK, Hankins S. Evaluation of a Heart Transplant Candidate. Curr Cardiol Rep 2017;19:133. [PMID: 29103157 DOI: 10.1007/s11886-017-0934-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
12 Vieira JL, Mehra MR. Heart transplantation candidacy. Curr Opin Organ Transplant 2021;26:69-76. [PMID: 33278151 DOI: 10.1097/MOT.0000000000000828] [Reference Citation Analysis]
13 Poller W, Haghikia A, Kasner M, Kaya Z, Bavendiek U, Wedemeier H, Epple HJ, Skurk C, Landmesser U. Cardiovascular Involvement in Chronic Hepatitis C Virus Infections - Insight from Novel Antiviral Therapies. J Clin Transl Hepatol 2018;6:161-7. [PMID: 29951361 DOI: 10.14218/JCTH.2017.00057] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
14 Farmakiotis D, Weiss Z, Brotherton AL, Morrissey P, Gohh R, Vieira K, Taylor LE, Garland JM. Successful Kidney Transplantation in a Recipient Coinfected with Hepatitis C Genotype 2 and HIV from a Donor Infected with Hepatitis C Genotype 1 in the Direct-Acting Antiviral Era. Case Reports Hepatol 2020;2020:7679147. [PMID: 32082657 DOI: 10.1155/2020/7679147] [Reference Citation Analysis]
15 Maghrabi HME, Elmowafy AY, Refaie AF, Elbasiony MA, Shiha GE, Rostaing L, Bakr MA. Efficacy and safety of the new antiviral agents for the treatment of hepatitis C virus infection in Egyptian renal transplant recipients. Int Urol Nephrol 2019;51:2295-304. [PMID: 31531807 DOI: 10.1007/s11255-019-02272-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Silva MJ, Pereira C, Loureiro R, Balsa C, Lopes P, Água-Doce I, Belo E, Martins HC, Coutinho R, Pádua E. Hepatitis C in a Mobile Low-Threshold Methadone Program. Eur J Gastroenterol Hepatol 2017;29:657-62. [PMID: 28151750 DOI: 10.1097/MEG.0000000000000843] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
17 Goetsch MR, Tamhane A, Varshney M, Kapil A, Overton ET, Towns GC, Franco RA. Direct-Acting Antivirals in Kidney Transplant Patients: Successful Hepatitis C Treatment and Short-Term Reduction in Urinary Protein/Creatinine Ratios. Pathog Immun 2017;2:366-75. [PMID: 29075676 DOI: 10.20411/pai.v2i3.211] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
18 Shafii AE, Harris DD 2nd, Baz M. Clearance of Hepatitis C Virus Prior to Lung Transplantation: A Case Report. Transplant Proc 2017;49:1682-4. [PMID: 28838464 DOI: 10.1016/j.transproceed.2017.06.002] [Reference Citation Analysis]
19 Vitrone M, Andini R, Mattucci I, Maiello C, Atripaldi L, Durante-Mangoni E, Zampino R. Direct antiviral treatment of chronic hepatitis C in heart transplant recipients. Transpl Infect Dis 2018;20. [PMID: 29139181 DOI: 10.1111/tid.12813] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
20 Carrier P, Essig M, Debette-Gratien M, Sautereau D, Rousseau A, Marquet P, Jacques J, Loustaud-Ratti V. Anti-hepatitis C virus drugs and kidney. World J Hepatol 2016; 8(32): 1343-1353 [PMID: 27917261 DOI: 10.4254/wjh.v8.i32.1343] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
21 Doucette KE, Halloran K, Kapasi A, Lien D, Weinkauf JG. Outcomes of Lung Transplantation in Recipients With Hepatitis C Virus Infection. Am J Transplant 2016;16:2445-52. [PMID: 26998739 DOI: 10.1111/ajt.13796] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
22 Sawinski D, Wong T, Goral S. Current state of kidney transplantation in patients with HIV, hepatitis C, and hepatitis B infection. Clin Transplant 2020;34:e14048. [PMID: 32700341 DOI: 10.1111/ctr.14048] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]